# ATC code L01

ATC code L01 Antineoplastic agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup L01 is part of the anatomical group L Antineoplastic and immunomodulating agents.
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL01. ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list. National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

## L01A Alkylating agents
### L01AA Nitrogen mustard analogues

    L01AA01 Cyclophosphamide
    L01AA02 Chlorambucil
    L01AA03 Melphalan
    L01AA05 Chlormethine
    L01AA06 Ifosfamide
    L01AA07 Trofosfamide
    L01AA08 Prednimustine
    L01AA09 Bendamustine
    L01AA10 Melphalan flufenamide

### L01AB Alkyl sulfonates

    L01AB01 Busulfan
    L01AB02 Treosulfan
    L01AB03 Mannosulfan

### L01AC Ethylene imines

    L01AC01 Thiotepa
    L01AC02 Triaziquone
    L01AC03 Carboquone

### L01AD Nitrosoureas

    L01AD01 Carmustine
    L01AD02 Lomustine
    L01AD03 Semustine
    L01AD04 Streptozocin
    L01AD05 Fotemustine
    L01AD06 Nimustine
    L01AD07 Ranimustine
    L01AD08 Uramustine

### L01AG Epoxides

    L01AG01 Etoglucid

### L01AX Other alkylating agents

    L01AX01 Mitobronitol
    L01AX02 Pipobroman
    L01AX03 Temozolomide
    L01AX04 Dacarbazine

## L01B Antimetabolites
### L01BA Folic acid analogues

    L01BA01 Methotrexate
    L01BA03 Raltitrexed
    L01BA04 Pemetrexed
    L01BA05 Pralatrexate

### L01BB Purine analogues

    L01BB02 Mercaptopurine
    L01BB03 Tioguanine
    L01BB04 Cladribine
    L01BB05 Fludarabine
    L01BB06 Clofarabine
    L01BB07 Nelarabine
    QL01BB90 Rabacfosadine

### L01BC Pyrimidine analogues

    L01BC01 Cytarabine
    L01BC02 Fluorouracil
    L01BC03 Tegafur
    L01BC04 Carmofur
    L01BC05 Gemcitabine
    L01BC06 Capecitabine
    L01BC07 Azacitidine
    L01BC08 Decitabine
    L01BC09 Floxuridine
    L01BC52 Fluorouracil, combinations
    L01BC53 Tegafur, combinations
    L01BC58 Decitabine, combinations
    L01BC59 Trifluridine, combinations

## L01C Plant alkaloids and other natural products
### L01CA Vinca alkaloids and analogues

    L01CA01 Vinblastine
    L01CA02 Vincristine
    L01CA03 Vindesine
    L01CA04 Vinorelbine
    L01CA05 Vinflunine
    L01CA06 Vintafolide

### L01CB Podophyllotoxin derivatives

    L01CB01 Etoposide
    L01CB02 Teniposide

### L01CC Colchicine derivatives

    L01CC01 Demecolcine

### L01CD Taxanes

    L01CD01 Paclitaxel
    L01CD02 Docetaxel
    L01CD03 Paclitaxel poliglumex
    L01CD04 Cabazitaxel
    L01CD51 Paclitaxel and encequidar

### L01CE Topoisomerase 1 (TOP1) inhibitors

    L01CE01 Topotecan
    L01CE02 Irinotecan
    L01CE03 Etirinotecan pegol
    L01CE04 Belotecan

### L01CX Other plant alkaloids and natural products

    L01CX01 Trabectedin

## L01D Cytotoxic antibiotics and related substances
### L01DA Actinomycines

    L01DA01 Dactinomycin

### L01DB Anthracyclines and related substances

    L01DB01 Doxorubicin
    L01DB02 Daunorubicin
    L01DB03 Epirubicin
    L01DB04 Aclarubicin
    L01DB05 Zorubicin
    L01DB06 Idarubicin
    L01DB07 Mitoxantrone
    L01DB08 Pirarubicin
    L01DB09 Valrubicin
    L01DB10 Amrubicin
    L01DB11 Pixantrone

### L01DC Other cytotoxic antibiotics

    L01DC01 Bleomycin
    L01DC02 Plicamycin
    L01DC03 Mitomycin
    L01DC04 Ixabepilone
    L01DC05 Utidelone

## L01E Protein kinase inhibitors
### L01EA BCR-ABL tyrosine kinase inhibitors

    L01EA01 Imatinib
    L01EA02 Dasatinib
    L01EA03 Nilotinib
    L01EA04 Bosutinib
    L01EA05 Ponatinib
    L01EA06 Asciminib

### L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

    L01EB01 Gefitinib
    L01EB02 Erlotinib
    L01EB03 Afatinib
    L01EB04 Osimertinib
    L01EB05 Rociletinib
    L01EB06 Olmutinib
    L01EB07 Dacomitinib
    L01EB08 Icotinib
    L01EB09 Lazertinib
    L01EB10 Mobocertinib
    L01EB11 Aumolertinib

### L01EC B-Raf serine-threonine kinase (BRAF) inhibitors

    L01EC01 Vemurafenib
    L01EC02 Dabrafenib
    L01EC03 Encorafenib

### L01ED Anaplastic lymphoma kinase (ALK) inhibitors

    L01ED01 Crizotinib
    L01ED02 Ceritinib
    L01ED03 Alectinib
    L01ED04 Brigatinib
    L01ED05 Lorlatinib

### L01EE Mitogen-activated protein kinase (MEK) inhibitors

    L01EE01 Trametinib
    L01EE02 Cobimetinib
    L01EE03 Binimetinib
    L01EE04 Selumetinib
    L01EE05 Mirdametinib

### L01EF Cyclin-dependent kinase (CDK) inhibitors

    L01EF01 Palbociclib
    L01EF02 Ribociclib
    L01EF03 Abemaciclib

### L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors

    L01EG01 Temsirolimus
    L01EG02 Everolimus
    L01EG03 Ridaforolimus
    L01EG04 Sirolimus

### L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors

    L01EH01 Lapatinib
    L01EH02 Neratinib
    L01EH03 Tucatinib

### L01EJ Janus-associated kinase (JAK) inhibitors

    L01EJ01 Ruxolitinib
    L01EJ02 Fedratinib
    L01EJ03 Pacritinib
    L01EJ04 Momelotinib

### L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors

    L01EK01 Axitinib
    L01EK02 Cediranib
    L01EK03 Tivozanib
    L01EK04 Fruquintinib

### L01EL Bruton's tyrosine kinase (BTK) inhibitors

    L01EL01 Ibrutinib
    L01EL02 Acalabrutinib
    L01EL03 Zanubrutinib
    L01EL04 Orelabrutinib
    L01EL05 Pirtobrutinib
    L01EL06 Tirabrutinib

### L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors

    L01EM01 Idelalisib
    L01EM02 Copanlisib
    L01EM03 Alpelisib
    L01EM04 Duvelisib
    L01EM05 Parsaclisib

### L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors

    L01EN01 Erdafitinib
    L01EN02 Pemigatinib
    L01EN03 Infigratinib
    L01EN04 Futibatinib

### L01EX Other protein kinase inhibitors

    L01EX01 Sunitinib
    L01EX02 Sorafenib
    L01EX03 Pazopanib
    L01EX04 Vandetanib
    L01EX05 Regorafenib
    L01EX06 Masitinib
    L01EX07 Cabozantinib
    L01EX08 Lenvatinib
    L01EX09 Nintedanib
    L01EX10 Midostaurin
    L01EX11 Quizartinib
    L01EX12 Larotrectinib
    L01EX13 Gilteritinib
    L01EX14 Entrectinib
    L01EX15 Pexidartinib
    L01EX17 Capmatinib
    L01EX18 Avapritinib
    L01EX19 Ripretinib
    L01EX21 Tepotinib
    L01EX22 Selpercatinib
    L01EX23 Pralsetinib
    L01EX24 Surufatinib
    L01EX25 Umbralisib
    L01EX26 Sitravatinib
    L01EX27 Capivasertib
    L01EX28 Repotrectinib
    QL01EX90 Toceranib

## L01F Monoclonal antibodies and antibody drug conjugates
### L01FA CD20 (clusters of differentiation 20) inhibitors

    L01FA01 Rituximab
    L01FA02 Ofatumumab
    L01FA03 Obinutuzumab

### L01FB CD22 (clusters of differentiation 22) inhibitors

    L01FB01 Inotuzumab ozogamicin
    L01FB02 Moxetumomab pasudotox

### L01FC CD38 (clusters of differentiation 38) inhibitors

    L01FC01 Daratumumab
    L01FC02 Isatuximab

### L01FD HER2 (human epidermal growth factor receptor 2) inhibitors

    L01FD01 Trastuzumab
    L01FD02 Pertuzumab
    L01FD03 Trastuzumab emtansine
    L01FD04 Trastuzumab deruxtecan
    L01FD05 Trastuzumab duocarmazine
    L01FD06 Margetuximab
    L01FD07 Zanidatamab

### L01FE EGFR (epidermal growth factor receptor) inhibitors

    L01FE01 Cetuximab
    L01FE02 Panitumumab
    L01FE03 Necitumumab

### L01FF PD-1/PDL-1 (programmed cell death protein 1/ death ligand 1) inhibitors

    L01FF01 Nivolumab
    L01FF02 Pembrolizumab
    L01FF03 Durvalumab
    L01FF04 Avelumab
    L01FF05 Atezolizumab
    L01FF06 Cemiplimab
    L01FF07 Dostarlimab
    L01FF08 Prolgolimab
    L01FF09 Tislelizumab
    L01FF10 Retifanlimab
    L01FF11 Sugemalimab
    L01FF12 Serplulimab
    L01FF13 Toripalimab

### L01FG VEGF/VEGFR (vascular endothelial growth factor) inhibitors

    L01FG01 Bevacizumab
    L01FG02 Ramucirumab

### L01FX Other monoclonal antibodies and antibody drug conjugates

    L01FX01 Edrecolomab
    L01FX02 Gemtuzumab ozogamicin
    L01FX03 Catumaxomab
    L01FX04 Ipilimumab
    L01FX05 Brentuximab vedotin
    L01FX06 Dinutuximab beta
    L01FX07 Blinatumomab
    L01FX08 Elotuzumab
    L01FX09 Mogamulizumab
    L01FX10 Olaratumab
    L01FX11 Bermekimab
    L01FX12 Tafasitamab
    L01FX13 Enfortumab vedotin
    L01FX14 Polatuzumab vedotin
    L01FX15 Belantamab mafodotin
    L01FX16 Oportuzumab monatox
    L01FX17 Sacituzumab govitecan
    L01FX18 Amivantamab
    L01FX19 Sabatolimab
    L01FX20 Tremelimumab
    L01FX21 Naxitamab
    L01FX22 Loncastuximab tesirine
    L01FX23 Tisotumab vedotin
    L01FX24 Teclistamab
    L01FX25 Mosunetuzumab
    L01FX26 Mirvetuximab soravtansine
    L01FX27 Epcoritamab
    L01FX28 Glofitamab
    L01FX29 Talquetamab
    L01FX31 Zolbetuximab
    L01FX32 Elranatamab
    L01FX33 Tarlatamab
    L01FX34 Odronextamab
    L01FX35 Datopotamab deruxtecan
    L01FX36 Patritumab deruxtecan

### L01FY Combinations of monoclonal antibodies and antibody drug conjugates

    L01FY01 Pertuzumab and trastuzumab
    L01FY02 Nivolumab and relatlimab
    L01FY03 Prolgolimab and nurulimab

## L01X Other antineoplastic agents
### L01XA Platinum compounds

    L01XA01 Cisplatin
    L01XA02 Carboplatin
    L01XA03 Oxaliplatin
    L01XA04 Satraplatin
    L01XA05 Polyplatillen

### L01XB Methylhydrazines

    L01XB01 Procarbazine

### L01XD Sensitizers used in photodynamic/radiation therapy

    L01XD01 Porfimer sodium
    L01XD03 Methyl aminolevulinate
    L01XD04 Aminolevulinic acid
    L01XD05 Temoporfin
    L01XD06 Efaproxiral
    L01XD07 Padeliporfin

### L01XF Retinoids for cancer treatment

    L01XF01 Tretinoin
    L01XF02 Alitretinoin
    L01XF03 Bexarotene

### L01XG Proteasome inhibitors

    L01XG01 Bortezomib
    L01XG02 Carfilzomib
    L01XG03 Ixazomib

### L01XH Histone deacetylase (HDAC) inhibitors

    L01XH01 Vorinostat
    L01XH02 Romidepsin
    L01XH03 Panobinostat
    L01XH04 Belinostat
    L01XH05 Entinostat
    L01XH06 Tucidinostat
    L01XH07 Resminostat

### L01XJ Hedgehog pathway inhibitors

    L01XJ01 Vismodegib
    L01XJ02 Sonidegib
    L01XJ03 Glasdegib

### L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors

    L01XK01 Olaparib
    L01XK02 Niraparib
    L01XK03 Rucaparib
    L01XK04 Talazoparib
    L01XK05 Veliparib
    L01XK06 Pamiparib
    L01XK52 Niraparib and abiraterone

### L01XL Antineoplastic cell and gene therapy

    L01XL01 Sitimagene ceradenovec
    L01XL02 Talimogene laherparepvec
    L01XL03 Axicabtagene ciloleucel
    L01XL04 Tisagenlecleucel
    L01XL05 Ciltacabtagene autoleucel
    L01XL06 Brexucabtagene autoleucel
    L01XL07 Idecabtagene vicleucel
    L01XL08 Lisocabtagene maraleucel
    L01XL09 Tabelecleucel
    L01XL10 Nadofaragene firadenovec
    L01XL11 Lifileucel
    L01XL12 Obecabtagene autoleucel

### L01XM Isocitrate dehydrogenase (IDH) inhibitors

    L01XM01 Enasidenib
    L01XM02 Ivosidenib
    L01XM03 Olutasidenib
    L01XM04 Vorasidenib

### L01XU Other antineoplastic agents (cont.)

    Empty group

### L01XX Other antineoplastic agents

    L01XX01 Amsacrine
    L01XX02 Asparaginase
    L01XX03 Altretamine
    L01XX05 Hydroxycarbamide
    L01XX07 Lonidamine
    L01XX08 Pentostatin
    L01XX10 Masoprocol
    L01XX11 Estramustine
    L01XX16 Mitoguazone
    L01XX18 Tiazofurine
    L01XX23 Mitotane
    L01XX24 Pegaspargase
    L01XX27 Arsenic trioxide
    L01XX29 Denileukin diftitox
    L01XX33 Celecoxib
    L01XX35 Anagrelide
    L01XX36 Oblimersen
    L01XX40 Omacetaxine mepesuccinate
    L01XX41 Eribulin
    L01XX44 Aflibercept
    L01XX46 Olaparib
    L01XX52 Venetoclax
    L01XX53 Vosaroxin
    L01XX57 Plitidepsin
    L01XX58 Epacadostat
    L01XX66 Selinexor
    L01XX67 Tagraxofusp
    L01XX69 Lurbinectedin
    L01XX72 Tazemetostat
    L01XX73 Sotorasib
    L01XX74 Belzutifan
    L01XX75 Tebentafusp
    L01XX77 Adagrasib
    L01XX78 Navitoclax
    L01XX79 Eflornithine
    L01XX80 Imetelstat
    L01XX81 Nirogacestat
    L01XX82 Darinaparsin
    L01XX83 Para-toluenesulfonamide
    L01XX84 Pelabresib
    L01XX85 Idroxioleic acid
    L01XX86 Calaspargase pegol
    QL01XX91 Tigilanol tiglate
    QL01XX92 Verdinexor

### L01XY Combinations of antineoplastic agents

    L01XY01 Cytarabine and daunorubicin
    L01XY04 Bifikafusp alfa and onfekafusp alfa